These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

42 related items for PubMed ID: 9007090

  • 1. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.
    Stüve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, Yong VW.
    Ann Neurol; 1996 Dec; 40(6):853-63. PubMed ID: 9007090
    [Abstract] [Full Text] [Related]

  • 2. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
    Leppert D, Waubant E, Bürk MR, Oksenberg JR, Hauser SL.
    Ann Neurol; 1996 Dec; 40(6):846-52. PubMed ID: 9007089
    [Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V.
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [Abstract] [Full Text] [Related]

  • 4. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H, Feng-Jun M, Osoegawa M, Minohara M, Murai H, Taniwaki T, Kira J.
    J Neurol Sci; 2004 Jul 15; 222(1-2):65-73. PubMed ID: 15240198
    [Abstract] [Full Text] [Related]

  • 5. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1.
    Prat A, Biernacki K, Antel JP.
    J Autoimmun; 2005 Mar 15; 24(2):119-24. PubMed ID: 15829404
    [Abstract] [Full Text] [Related]

  • 6. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.
    Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, Tak PP.
    Arthritis Rheum; 2000 Feb 15; 43(2):270-4. PubMed ID: 10693865
    [Abstract] [Full Text] [Related]

  • 7. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer.
    Lou J, Gasche Y, Zheng L, Giroud C, Morel P, Clements J, Ythier A, Grau GE.
    Lab Invest; 1999 Aug 15; 79(8):1015-25. PubMed ID: 10462039
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P, Romano MR, Boccardi B, Lombardo F, Moscato G, Mosti S, Baldini C, Nuti S, Meucci G, Rossi B.
    Rev Neurol; 1999 Aug 15; 29(10):893-9. PubMed ID: 10637835
    [Abstract] [Full Text] [Related]

  • 11. Interferon beta for glomerulonephritis?
    Wardle EN.
    Saudi J Kidney Dis Transpl; 2007 Sep 15; 18(3):333-6. PubMed ID: 17679741
    [Abstract] [Full Text] [Related]

  • 12. Beta-interferon unbalances the peripheral T cell proinflammatory response in experimental autoimmune encephalomyelitis.
    Martín-Saavedra FM, Flores N, Dorado B, Eguiluz C, Bravo B, García-Merino A, Ballester S.
    Mol Immunol; 2007 Jul 15; 44(14):3597-607. PubMed ID: 17420051
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
    Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
    [Abstract] [Full Text] [Related]

  • 14. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H.
    J Neuroimmunol; 2004 Oct 09; 155(1-2):172-82. PubMed ID: 15342209
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 09; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 17. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
    Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ.
    J Neurol; 2003 Sep 09; 250(9):1037-43. PubMed ID: 14504963
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb 09; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9.
    Stuve O, Chabot S, Jung SS, Williams G, Yong VW.
    J Neuroimmunol; 1997 Dec 09; 80(1-2):38-46. PubMed ID: 9413258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.